Lacidipine-13C4
Product Specifications
UNSPSC Description
Lacidipine-13C4 is 13C labeled Lacidipine (HY-B0347). Lacidipine is an orally active and highly selective L-type calcium channel blocker that acts on smooth muscle calcium channels, primarily dilates peripheral arteries, reduces peripheral resistance, and has long-lasting anti-hypertensive activity. Lacidipine protects HKCs from apoptosis induced by ATP depletion and recovery by modulating the caspase-3 pathway. Lacidipine can be used in studies of hypertension, atherosclerosis and acute kidney injury (AKI)[1][2].
Target Antigen
Apoptosis; Calcium Channel; Caspase; Isotope-Labeled Compounds; Reactive Oxygen Species
Type
Isotope-Labeled Compounds
Related Pathways
Apoptosis;Immunology/Inflammation;Membrane Transporter/Ion Channel;Metabolic Enzyme/Protease;Neuronal Signaling;NF-κB;Others
Applications
Neuroscience-Neurodegeneration
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/lacidipine-13c4.html
Solubility
10 mM in DMSO
Smiles
O=[13C]([13C]1=C(C)NC(C)=[13C]([13C](OCC)=O)C1C2=CC=CC=C2/C=C/C(OC(C)(C)C)=O)OCC
Molecular Weight
459.51
References & Citations
[1]Zhang A, et al. Lacidipine attenuates apoptosis via a caspase-3 dependent pathway in human kidney cells. Cell Physiol Biochem. 2013;32(4):1040-9. |[2]Cristofori P, et al. The calcium-channel blocker lacidipine reduces the development of atherosclerotic lesions in the apoE-deficient mouse. J Hypertens. 2000 Oct;18(10):1429-36. |[3]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-B0347S3/Lacidipine-13C4-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-B0347S3/
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items